Key facts
- Aspen Neuroscience’s last known valuation is $346.0M (Sep 2025).
- It has raised $379.3M; the latest was Later Stage VC ($115.3M) in Sep 2025.
- Notable investors include Gaingels, GV, Alexandria Venture Investments, OrbiMed, Mirae Asset Capital — 26 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 26 names
- ·Watchlist + deal alerts for Aspen Neuroscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Aspen Neuroscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aspen Neuroscience
Developer of autologous cell therapies and personalized medicines designed for a broad spectrum of diseases, starting with Parkinson's disease. The company's platform reprograms a patient's own cells into iPSC-derived neuronal precursors, incorporates automation, machine-learning-based quality control, and robotics-driven manufacturing, and places the resulting cells directly into targeted brain regions without immunosuppression, enabling the neurology market to access personalized therapeutic options aimed at restoring dopamine-related function.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2018
- Employees
- 123
- Website
- aspenneuroscience.com/
- Ownership
- Privately Held (backing)
Aspen Neuroscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aspen Neuroscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aspen Neuroscience in its N-PORT filings yet. We sweep new filings monthly.